Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q4 2025 value amounting to $329.5 million.

  • Enanta Pharmaceuticals' Liabilities and Shareholders Equity fell 548.96% to $329.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was $1.2 billion, marking a year-over-year decrease of 1973.21%. This contributed to the annual value of $280.7 million for FY2025, which is 2546.65% down from last year.
  • Latest data reveals that Enanta Pharmaceuticals reported Liabilities and Shareholders Equity of $329.5 million as of Q4 2025, which was down 548.96% from $280.7 million recorded in Q3 2025.
  • Enanta Pharmaceuticals' 5-year Liabilities and Shareholders Equity high stood at $495.2 million for Q2 2023, and its period low was $280.7 million during Q3 2025.
  • Over the past 5 years, Enanta Pharmaceuticals' median Liabilities and Shareholders Equity value was $392.0 million (recorded in 2022), while the average stood at $389.8 million.
  • As far as peak fluctuations go, Enanta Pharmaceuticals' Liabilities and Shareholders Equity soared by 2854.39% in 2023, and later crashed by 2546.65% in 2025.
  • Quarter analysis of 5 years shows Enanta Pharmaceuticals' Liabilities and Shareholders Equity stood at $440.6 million in 2021, then fell by 21.12% to $347.5 million in 2022, then rose by 23.3% to $428.5 million in 2023, then decreased by 18.64% to $348.6 million in 2024, then fell by 5.49% to $329.5 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $329.5 million for Q4 2025, versus $280.7 million for Q3 2025 and $301.0 million for Q2 2025.